Anlotinib, Vincristine and Irinotecan (AVI) for Advanced Ewing Sarcoma after Failure of Standard Multimodal Therapy: A Two-cohort, Phase Ib/II Trial

CONCLUSION: The combination of vincristine, irinotecan and anlotinib demonstrated an acceptable toxicity profile and promising clinical efficacy in patients with advanced EWS.IMPLICATIONS FOR PRACTICE: This is the first trial to evaluated irinotecan-based regimen in combination with anti-angiogenesis TKIs in Ewing sarcoma. A 3+3 design with dose de-escalation was used to determine the most appropriate dose of irinotecan in each cohort. The next dose-expanding phase II portion employed a conventional two-stage study design model. The objective response rate was 62.5% for adults and 83.3% for children. Median overall survival was not matured. We demonstrated that the combination of vincristine, irinotecan and anlotinib demonstrated an acceptable toxicity profile and promising clinical efficacy in patients with advanced EWS.PMID:33611805 | DOI:10.1002/onco.13726
Source: The Oncologist - Category: Cancer & Oncology Authors: Source Type: research